Clinical pharmacy in the era of an injection-free regimen for drug-resistant tuberculosis
Abstract
Tuberculosis (TB) is the ninth leading cause of death worldwide with the 2019 global report placing South Africa (SA) among the six high TB burden countries.1 Globally, treatment success rates (cured and completed treatment) for multidrug resistant tuberculosis (MDR-TB) in the 2016 cohort were 56% and for extensively drug-resistant TB (XDR-TB) 39%. Despite major investments in medicine, diagnostics and programmatic management, low treatment success rates, high failure and loss to follow up rates have been reported for DR-TB globally and in SA.
Published
2020-12-11
Issue
Section
Forum
By submitting manuscripts to SAPJ, authors of original articles are assigning copyright to Medpharm Publications (Pty) Ltd. Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in SAPJ for educational and research purposes without obtaining permission.